AOD-9604
Advanced Obesity Drug 9604 (Tyr-hGH 177-191 Synthetic Fragment)
AOD-9604 is a synthetic 16-amino-acid peptide fragment corresponding to the lipolytic C-terminus of human growth hormone (hGH 177-191) with an added N-terminal tyrosine residue. Studied for its capacity to stimulate beta-3 adrenergic lipolytic pathways without affecting insulin sensitivity or serum IGF-1 levels.
Indexed for laboratory in vitro receptor binding assays and cellular synthesis research. Commercial materials are procured as non-clinical reagents under verified laboratory standards.
Chemical Structure & Metrics
Structured Chemical & Preclinical Profile
1. Chemical Identity & Sequence Architecture
AOD-9604 (Advanced Obesity Drug 9604 (Tyr-hGH 177-191 Synthetic Fragment)) is an analytically characterized peptide with empirical formula C78H123N23O23S2 (MW 1815.12 g/mol). CAS Registry: 221231-10-3.
2. Primary Preclinical Signaling Axis
Investigated in preclinical assays for cellular signaling: Selective upregulation of beta-3 adrenergic receptor expression on adipocytes, stimulating hormone-sensitive lipase.
3. Physical Formats & Delivery Matrices
Synthesized predominantly as high-purity lyophilized powder cakes, with secondary pre-metered pen cartridges and solution atomizers cataloged across vendors.
4. Reconstitution & Analytical Handling
Recommended reconstitution with Bacteriostatic Water USP or Sterile Saline. Lyophilized cake stored at -20°C desiccated. Solution stable at 2°C to 8°C refrigerated (stable 21 days).
Signaling Pathways & Laboratory Handling Protocols
Documented Receptor Pathways & In Vitro Signaling
Selective upregulation of beta-3 adrenergic receptor expression on adipocytes, stimulating hormone-sensitive lipase.
Inhibition of acetyl-CoA carboxylase activity, suppressing de novo lipogenesis in cultured adipose tissue.
Absence of binding to human growth hormone receptors, preventing IGF-1 induction or diabetogenic hyperglycemia.
Chondrogenesis induction and extracellular matrix accumulation in cartilage explants.
Subject of academic investigation for beta-3 adrenergic receptor lipolytic signaling and chondrocyte proteoglycan synthesis in preclinical models.
Handling Parameters
Peptide Dilution & Reconstitution Calculator
Compute stock concentrations, micro-pipetting draw volumes, and U-100 syringe units with zero procedural guesswork.
Slowly introduce bacteriostatic diluent against the internal glass vial wall. Swirl gently in a circular horizontal rotation. Never shake or vortex vigorously to prevent mechanical shearing of delicate peptide bonds. Store reconstituted stock at 2°C–8°C.
Partner & Vendor Catalogues for AOD-9604
Independent partner directory providing research-grade lyophilized vials, cartridges, atomizers, and reconstitution solvents.
Category hub featuring research-grade lyophilized vials, pens, and blends.
Full catalogue category hub with multiple mg vial sizes and blends.
Dedicated category hub listing research vials and cartridges.
UK-stocked research reagent catalogue hub featuring batch-verified peptide lots.
Global catalogue hub including international dispatch batches.
Academic Bibliography & Preclinical Studies for AOD-9604
Primary academic indexing sourced from PubMed and peer-reviewed biotechnology journals documenting molecular mechanisms and in vitro cellular response.
The Effects of Human GH and Its C-Terminal Fragment (AOD9604) on Lipid Metabolism
Safety and tolerability of the hexadecapeptide AOD9604 in humans
AOD9604 enhances in vitro chondrogenic differentiation of mesenchymal stem cells
Frequently Asked Chemical & Analytical Questions
Authoritative scientific clarifications regarding AOD-9604 classification, molecular pathways, and laboratory protocols.
AOD-9604 (Advanced Obesity Drug 9604 (Tyr-hGH 177-191 Synthetic Fragment)) is an analytically characterized peptide compound with empirical molecular formula C78H123N23O23S2 and molecular weight 1815.12 g/mol. It is indexed under CAS Registry Number 221231-10-3 and categorized in research literature under Metabolic & Incretin Signaling.